The Form 4 filing, which reports insider stock activity to the SEC, was submitted on November 16, 2026. All six sales took place that day.
Oruka Therapeutics is a biotechnology company in the healthcare sector. Joana Goncalves serves as its chief medical officer.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-16 |
| Date of Latest Transaction | 2026-11-16 |
| Buy/Sell | sell |
| Transaction Count | 6 |
| Shares Transacted | 7,000 |
| Price | $100.96 |
| Total Transaction Value | $706,699.72 |
| Insider | |
| Ticker Symbol | ORKA |
| Company | Oruka Therapeutics, Inc. |
| Insider Name | Goncalves Joana |
| Insider Title | Chief Medical Officer |
| Sector - Industry | Healthcare - Biotechnology |
| Holdings | |
| Total Shares Owned After Transaction | 31,771 |
| Position Size Change | 18.05% |
| Filing | |
| Filing Date | 2026-11-16 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
This was a sale of ORKA shares, reported with transaction code S. The filing covers six sale transactions by one insider, Joana Goncalves.
What was the average price of the transaction?
The average sale price was $100.96 per share across the six transactions.
How did this transaction affect the insider's holdings?
The sale involved 7,000 shares, leaving 31,771 shares reported as owned afterward. The shares sold made up 18.05% of the shares reported as owned before the sale.
What's the total transaction value?
The total value was $706,699.72 for all six sales.
Are there any special circumstances around this transaction?
Yes. The available information includes a Rule 10b5-1 trading-plan reference for this filing. These plans set trading instructions in advance. The reference may apply to the filing as a whole. No footnote text was provided to confirm which of the six sales it covers. The plan's start date and trading schedule are unknown. The reference does not show why the shares were sold.
For research purposes only; not investment advice.